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Abstract
B ackgrounds: To determine the true incidence o f hGISA/GISA and its consequent clinical impact, 
methods must be defined that w ill reliably and reproducibly discriminate these resistant phenotypes 
from vancomycin susceptible S. aureus (VSSA).
M ethods: This study assessed and compared the ability o f eight Dutch laboratories under blinded 
conditions to  discriminate VSSA from hGISA/GISA phenotypes and the intra- and inter-laboratory 
reproducibility o f agar screening plates and the Etest method. A  total o f 25 blinded and unique 
strains (10 VSSA, 9 hGISA and 6 GISA) were categorized by the PAP-AUC method and PFGE typed 
to  eliminate clonal duplication. A ll strains were deliberately added in quadruplets to  evaluate intra­
laboratory variability and reproducibility o f the methods. Strains were tested using three agar 
screening methods, Brain Heart Infusion agar (BHI) + 6 |ig/ml vancomycin, Mueller H inton agar 
(MH) + 5 |ig/ml vancomycin and MH + 5 |ig/ml teicoplanin) and the Etest macromethod using a 2 
McFarland inoculum.
R esults and  D iscussion: The ability to  detect the hGISA/GISA phenotypes varied significantly 
between methods and phenotypes. BHI vancomycin and MH vancomycin agar screens lacked the
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ability to  detect hGISA. The MH teicoplanin agar screen was more sensitive but still inferior to  
Etest that had a sensitivity o f 98.5% and 99.5%, fo r hGISA and GISA, respectively. Intra- and inter­
laboratory reproducibility varied between methods w ith poorest performance seen w ith BHI 
vancomycin.
C onclusion: This is the first multi-center blinded study to  be undertaken evaluating various 
methods to  detect GISA and hGISA. These data showed that the ability o f clinical laboratories to  
detect GISA and hGISA varied considerably, and that screening plates w ith  vancomycin have a poor 
performance in detecting hGISA.
Background
Since the advent of the first glycopeptide intermediately 
susceptible S. aureus (GISA) and its heterogeneous variant 
(hGISA) in 1997, debate still ensues as to their clinical sig­
nificance [1-9]. This perhaps has been compounded by 
the discovery of the vanA-mediated glycopeptide resistant
S. aureus from the US where the glycopeptide minimum 
inhibitory concentrations are demonstrably higher and 
testing issues are also present, but less problematic 
[10,11]. However, the detection of GISA and hGISA are 
hampered by the insensitivity of the basic format of stand­
ard methods for capturing these phenotypes. Seven years 
after the publication of Mu50 (GISA) and Mu3 (hGISA), 
very little has been resolved as to which methods are the 
most reliable and reproducible. This in part is due to the 
different definitions ascribed to GISA and hGISA that are 
subject to methodological differences and variations in 
(clinical) breakpoints and cut-off values [12,13]. Whilst 
GISA has a more "homogeneous" resistant population 
resulting in a higher, stable (thus more reproducible) van­
comycin MIC, h-GISA expresses the resistance at approxi­
mately 1/106 of the native population thereby eluding 
detection by conventional methods. However, strains test­
ing positive by these methods share phenotypic character­
istics such as a thickened looser cross-linked cell wall with 
glycopeptide intermediate S. aureus (GISA) [14-16]. Thus, 
it is possible that hGISA and GISA strains represent the 
extremes of a common phenotype conferring reduced sus­
ceptibility to glycopeptides.
Controlled studies have shown that GISA strains inhibited 
by a higher vancomycin MIC value are more frequently 
associated with clinical failures than VSSA. In contrast, the 
clinical relevance of h-GISA remains controversial. How­
ever, numerous case reports have associated hGISA with a 
poor response to glycopeptide therapy but studies of their 
clinical significance have been hampered by difficulties in 
detecting these strains in the diagnostic laboratory and a 
lack of confirmatory tests. However, a recent observa­
tional study comparing the clinical features of bacterae- 
mia due to hGISA (defined by population analysis 
profiles -  area under the curve [PAP-AUC ratio]) and fully 
vancomycin susceptible MRSA found that hGISA infec­
tion was associated with significantly longer time to defer­
vescence (mean 35 vs 2.9 days), and duration of 
bacteraemia (mean 35 vs. 6.4 days), and a non-significant 
increase in length of hospital stay (107 vs 37 days) [17]. 
Clinical failure of vancomycin treatment (defined as fever 
and bacteraemia >7 days into vancomycin therapy) 
occurred in 100% (5/5) hGISA cases compared to 2.1% 
(1/48) MRSA cases.
Studies of the prevalence of GISA and hGISA have also 
suffered from various non-standardized methods for 
detection and confirmation of these strains so that inter­
country frequencies differ significantly. These differences 
may reflect genuine geographical variation but are likely 
to be due to methodological inconsistencies. To facilitate 
the detection of GISA and in particular hGISA, methods 
have been proposed where media, inoculum, and period 
of incubation have been altered [5,18-20]. These include 
the antibiotic gradient plate, agar screening plates, Etest, 
population studies (PS) and population analysis profiles
-  area under the curve assays (PAP-AUC) [21,22]. The 
most reliable of these is the PAP-AUC; however, it is both 
specialized and labor intensive. The implementation of 
these methods for detecting resistance will depend on 
their intra- and inter-laboratory reproducibility. We 
describe herein the first multi-center blinded study com­
paring the reliability of four screening methods in an 
eight-center setting; namely, to assess and compare the 
inter-laboratory reproducibility of three "agar screening 
plates" and the Etest "macromethod" in discriminating 
VSSA from hGISA/GISA phenotypes.
Methods
G ISA  and h-GISA strains
The study included an international collection of 25 
unique strains composed of 10 VSSA, 9 hGISA and 6 GISA 
as determined by PAP-AUC ratio as previously described 
[22]. The strains used represented the five major hospital 
lineages as previously described [6]. All strains were delib­
erately added in quadruplets to evaluate intra-laboratory 
variability and reproducibility of the methods. Each of the 
eight participating laboratories received 100 "numbered" 
isolates. Investigators were blinded with regard to the iso­
lates' phenotype and were unaware that the collection 
contained replicates.
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Agar an tib io tic  screening p la tes
Laboratories were asked to perform three screening meth­
ods. The first utilized Brain Heart Infusion (BHI) (Becton 
Dickinson, Cockeysville, Md.) agar supplemented with 6 
|ig/ml of vancomycin (BHI-van) [16]. The other two agar­
screening media were prepared in a similar manner as the 
BHI medium. All media were centrally supplied. They 
consisted of Mueller Hinton agar (MH- Becton Dickinson, 
Cockeysville, Md.) with vancomycin (5 |ig/ml) (MH-van) 
and with teicoplanin (5 |ig/ml) (MH-teico), respectively 
[19,23]. Inoculum was prepared as previously described. 
10 |il of the inoculum suspension was used for spot inoc­
ulation of the agar screening plates. Plates were incubated 
at 35°C for 18 and 40 hours. Growth was reported after 
both 24 and 48 hours.
E test m acrom ethod
The Etest macromethod for hGISA/GISA testing as recom­
mended by the manufacturer was used as previously 
described [20]. Essentially, numerous isolated colonies 
from an overnight agar culture were suspended into MH 
broth to achieve a turbidity corresponding to 2 McFar­
land. 100 |il of the inoculum suspension were pipetted 
onto a standard BHI agar plate and streaked out evenly 
and then left to dry completely. Etest vancomycin and 
teicoplanin MIC gradient strips (AB BIODISK, Solna, Swe­
den) were then applied and the plates incubated at 35°C 
and read at 24 and 48 hours independently by two tech­
nicians. The point of complete inhibition of all growth, 
including hazes, microcolonies and isolated colonies in 
the inhibition ellipse, was used as the end-point. Etest 
macromethod results were interpreted as positive for 
hGISA/GISA when both vancomycin and teicoplanin 
modified MICs were > 8 or when the teicoplanin MIC 
alone was > 12. Etest MIC values that fell in between dilu­
tions e.g. 6 |ig/ml were not rounded up.
C alcu la tion  o f sensitivity and specific ity
All results were entered into SPSS [24]. The sensitivity (= 
the probability that a "positive" case is correctly classified, 
thus the false negative rate, and the specificity (= the prob­
ability that a "negative" case is correctly classified, or the 
false positive rate) were calculated. Furthermore, Cohen's 
kappa was calculated as a measure that expresses the 
agreement between the evaluations of two raters when 
both are rating the same object. A value of 1 indicates per­
fect agreement. A value of 0 indicates that agreement is no 
better than chance.
Results and discussion 
Instab ility o f  h-G ISA phenotype
All GISA and hGISA strains that consistently gave a VSSA 
phenotype yet were originally categorized as a GISA/ 
hGISA as judged by PAP-AUC (ratio >0.9), were re-sent to 
the central laboratory to re-confirm their original PAP-
AUC profile. Two strains (a Norwegian hGISA and a 
French hGISA) had lost their ability to express the hetero­
geneous form of the resistance (PAP-AUC ratios of 0.82 
and 0.75, respectively) for vancomycin and were retro­
spectively excluded from the study. All GISA strains main­
tained their resistant phenotype.
Sp ec ific ity  and sensitivity
The sensitivity and specificity of agar screening methods 
and the Etest macromethod are displayed in table 1. The 
specificity (i.e. no false positives) of all test methods to 
define VSSA varied considerably. MH-van and BHI-van 
gave unacceptable values of 58.7% and 68.4%, respec­
tively. In contrast, both MH-teico and Etest macromethod 
gave acceptable values of 92.1% and 93.3%, respectively. 
The ability of each method to detect GISA and hGISA also 
varied considerably (Table 1). The GISA isolates (as 
defined by conventional MIC methodology) were virtu­
ally all detected by Etest (sensitivity of 99.5%). The agar 
screening methods varied from one another markedly, the 
highest sensitivity was MH-teico (95.8%), followed by 
BHI-van (85.9%) and the lowest was MH-van (50.8%). 
Predictably, the ability of each method to detect h-GISA 
varied immensely. Sensitivity values for Etest, MH-teico, 
BHI-van and MH-van were 98.5%, 85.0%, 4.5% and 
1.0%, respectively. Whilst the ability of Etest, and to a 
lesser degree MH-teico, to detect hGISA maybe regarded 
as acceptable, the sensitivity values for BHI-van and MH- 
van are clearly not.
The inter-laboratory reproducibility of the methods as cal­
culated by Cohen's kappa on the quadruplicate samples 
of each strain is depicted in Table 2. Cohen's kappa values 
could not be calculated for MH-van for VSSA, MH-van for 
hGISA and Etest for GISA due to unbalanced variance of 
components. The inter-laboratory reproducibility for 
VSSA was acceptable for MH-teico (0.80) and Etest (0.70), 
and poor for BHI-van (0.30). For h-GISA, BHI-van also 
performed poorly (0.05) compared to MH-teico (0.93) 
and Etest (0.88). The reproducibility to detect GISA was
T a b le  1: S e n s itiv ity  and  s p e c if ic ity  o f  ag a r sc re e n in g  p la te s  and 
th e  E te s t m a c ro m e th o d
correctly  identified (%)
BHI-van MH-van M H-teico Etest
Overall
Sensitivity
44.4 25.3 90.3 99.0
Overall
Specificity
h-GISA
68.4 58.7 92.1 93.3
Sensitivity
GISA
4.5 1.0 85.0 98.5
Sensitivity 85.9 50.5 95.8 99.5
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T a b le  2: In te r - la b o ra to ry  re p ro d u c ib i l i ty  o f  a g a r sc re e n in g  p la te s  
and  E te s t m a c ro m e th o d
BHI-van MH-van M H-teico Etest
VSSA 0,29 * 0,80 0,70
h-GISA 0,05 * 0,93 0,88
GISA 0,70 0,91 0,89 *
A ll isolates 0,97 0,95 0,96 *
*  = unable to  estimate due to  unbalanced variance components
generally better, namely 0.70 for BHI-van, 0.91 for MH- 
van, and 0,89 for MH-teico. The overall intra-laboratory 
reproducibility was predictably high with values of 0.97, 
0.95 and 0.96 for BHI-van, MH-van and MH-teico, respec­
tively.
The marked paucity in controlled studies evaluating the 
clinical outcome of patients infected with either hGISA or 
GISA may be due to the difficulty in detecting these resist­
ant phenotypes. Much debate still ensues regarding the 
clinical significance of GISA and especially hGISA and 
which methods are best employed to detect them. Meth­
ods available vary considerably both at an intra- and inter­
country level. For example in the USA, BHI agar screen 
containing 6 |ig/ml of vancomycin is commercially avail­
able yet teicoplanin is not available, partly because the 
drug is not licensed for clinical use in the US. Conse­
quently, most laboratories in the US will preferentially use 
BHI-van (6 |ig/ml) whereas European laboratories will 
prefer MH-teico (5 |ig/ml) or BHI with 4 |ig/ml vancomy­
cin [2,23]. Inevitably, the variation in prevalence of hGISA 
and GISA from these regions may reflect the performance 
of the methodologies employed rather than the true inci­
dence of the resistance. It is well known that both hGISA 
and GISA are physiologically different from VSSA, pos­
sessing a thicker, less cross-linked cell wall and are usually 
nutritionally deficient and considerably slower growing 
[8]. Accordingly, standard antimicrobial susceptibility 
testing methods are not often appropriate in detecting 
these phenotypes and studies with richer media, heavier 
inoculum (to detect the low frequency resistance of 1/106) 
and extended period of incubation have been docu­
mented as alternative testing conditions. However, such 
non-standardized methods are difficult to control and 
very few studies have been undertaken examining their 
inter- and intra-laboratory variability.
This is the first multi-center blinded hGISA/GISA study 
and has highlighted some of strengths and potential defi­
ciencies within the methodological protocol. For instance, 
on re-evaluating two strains that gave drastically out-lying 
results, two hGISA had "lost" their resistance and reverted 
to VSSA on being transferred from the UK to the Nether­
lands clearly demonstrating the instability of some strains
belonging to the hGISA phenotype. The methods chosen 
for this study are those that have been proposed by vari­
ous groups as an initial screen to detect hGISA/GISA. The 
phenotypic categorization of the strains used in this study 
was based on PAP-AUC, a specialized method chosen by 
the referral laboratory that is specifically designed to 
detect resistant sub-populations that exist with hGISA. 
Perhaps not surprisingly, the screening methods chosen 
for this study (agar screening plates and Etest mac­
romethod) varied considerably in their ability to detect 
hGISA and GISA as judged by the participating laborato­
ries. The poorest performing method under these condi­
tions was MH-van (5 ^g/ml) with a sensitivity of 25.3% 
and a specificity of 58.7%. Whilst, BHI-van (6 ^g/ml) per­
formed better, its sensitivity (44.4%) and specificity 
(68.4%) should be deemed as sub-optimal and caution 
should be advised when using this screening method. 
Both Etest macromethod and MH-teico performed very 
well with a sensitivity of 99.0% and 90.3%, respectively. 
Although most methods could detect the higher and more 
homogeneous level of resistance in GISA (apart from MH- 
van), the biggest variation between the methods arose in 
detecting hGISA. This in part may be explained by the dif­
ference in inoculum and why using a higher inoculum (2 
McFarland) proves the rate of detecting the 1/106 of the 
cells expressing this type of resistance.
The inter-laboratory variability of these methods varied 
enormously. The poorest of these was BHI-van that gave a 
Cohen's kappa value of 0.05 and 0.7 for hGISA and GISA, 
respectively. Comparatively, the other methods did much 
better and could be regarded as acceptable. The inter-lab­
oratory variation of a screening method is vitally impor­
tant if routine microbiology laboratories are going to be 
encouraged to use such methods. Both MH-teico and Etest 
performed well, with the latter possessing the highest sen­
sitivity and specificity. Despite the reluctance of some lab­
oratories in implementing the Etest macromethod due to 
its non-standardized format, the participating laborato­
ries in this study were able to employ it with very few dif­
ficulties.
Conclusion
The debate on the clinical significance of GISA, and in par­
ticular hGISA is likely to continue for the foreseeable 
future [1,6,7]. However, some studies clearly demonstrate 
that h-GISA is associated with poorer clinical outcome 
and longer hospitalization [17]. The implementation of 
non-standardized methods to detect relatively rare and 
unusual forms of resistance (i.e. GISA and hGISA) must be 
ratified using multi-center data carried out under blind 
conditions such as those outlined in this study. The clini­
cal significance of GISA and particularly hGISA can only 
be truly assessed by first employing appropriate methods 
to detect it.
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